Faculty of Social Sciences, City University of Applied Sciences, Bremen, Germany.
Institute of Psychology and Transfer, University of Bremen, Germany.
J Bodyw Mov Ther. 2020 Apr;24(2):4-10. doi: 10.1016/j.jbmt.2020.01.003. Epub 2020 Feb 6.
The current study investigated the motor and the non-motor outcomes of Nordic Walking (NW) in Parkinson's disease (PD) using a systematic review of studies with any design.
The search of PubMed, PsycInfo, Medline and SCOPUS until November 2018 identified k = 13 relevant studies: five randomised controlled-trials (RCTs) and eight observational studies. Study designs, intervention, patient and outcome details were coded. Study quality was assessed with the Physiotherapy Evidence Database scale.
All studies reported either benefits or no effects of NW in 318 patients at the early stages of PD with low to moderate severity. NW was well accepted and relatively safe. Symptom severity, walking speed and gait pattern consistently improved after 4 - 24 weeks of NW relative to baseline or any control condition during the ON-phases of pharmacotherapy. The NW benefits were less consistent during the OFF-phases and at the follow-up in the absence of regular training.
NW may contribute to the maintenance of the overall mobility in addition to pharmacotherapy. Since the quality of studies was poor to moderate, future single-blind RCTs should investigate the clinical relevance of the NW outcomes and the training parameters necessary to optimise the benefits of NW in PD.
本研究通过对任何设计的研究进行系统综述，调查了北欧健走（NW）对帕金森病（PD）的运动和非运动结果。
截至 2018 年 11 月，通过对 PubMed、PsycInfo、Medline 和 SCOPUS 的搜索，确定了 k=13 项相关研究：五项随机对照试验（RCT）和八项观察性研究。对研究设计、干预、患者和结果细节进行了编码。使用物理治疗证据数据库量表评估研究质量。
所有研究均报告了 NW 在 318 名处于 PD 早期、病情较轻至中度的患者中的益处或无影响。NW 被广泛接受且相对安全。与基线或药物治疗的 ON 期的任何对照条件相比，NW 在 4-24 周后可显著改善症状严重程度、步行速度和步态模式。在药物治疗的 OFF 期和随访期间，NW 的益处不那么一致，而且在没有定期训练的情况下也不明显。
NW 可能有助于在药物治疗的基础上维持整体运动能力。由于研究质量较差，未来的单盲 RCT 应研究 NW 结果的临床相关性以及优化 NW 在 PD 中的获益所需的训练参数。
